-
Basel, November 23, 2022 — As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.MalariaChildren's HealthAfricaAccess to Healthcare
-
Access to HealthcareAfricaEye CareEye DisordersOphthalmology
-
Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and malaria in conjunction with the Kigali Summit on Malaria and NTDs alongside the 26th Commonwealth Heads of Government (CHOGM) meeting. This summit…MalariaInfectious DiseasesFuture of HealthcareAfricaAccess to Healthcare
-
Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.
Access to HealthcareAfricaChildren's HealthNovartis Access -
Nairobi, June 2, 2022 – Novartis today announced a partnership with the American Society of Hematology (ASH) to provide six additional African nations with technology that is already being used in Ghana to document and share the diagnosis of babies with sickle cell disease. Early diagnosis is key to managing the disease and ensuring better health…Genetic DiseaseAfricaAccess to Healthcare
-
Basel, September 29, 2021 — As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study.MalariaAfrica
-
Basel, January 19, 2021 — Novartis and GSK today announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.AfricaAccess to Healthcare
-
Basel, February 17, 2021 — Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The project…Tropical DiseasesInnovationAfricaAccess to Healthcare
-
The digital press release with multimedia content can be accessed here:MalariaDisease EradicationAfrica
-
Basel, December 9, 2019 — “We see sickle cell as a painful disease, but too often we don't translate how that pain affects the lives of our patients – can they go to school, can they work, can they enjoy their families? These are things many of us take for granted,” said Ifeyinwa Osunkwo, MD, MPH, Founder and Director, Sickle Cell Disease…Tropical DiseasesScientific ResearchAfrica
-
Basel, February 25, 2020 – Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.Global Health PartnershipsAfricaAccess to Healthcare
-
The Hague, the Netherlands; Geneva and Basel, Switzerland, March 3, 2020. The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium will support the development of new treatments for malaria in the most-at-…MalariaAfricaAccess to Healthcare
Pagination
- 1
- 2
- › Next page